Clinical Trial

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

Study acronym: RAGE
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy. The Investigators hypothesize that there will be no significant interaction with Azeliragon and chemotherapy and that targeting the RAGE pathway will decrease anthracycline related cardiotoxicity and chemotherapy related cognitive decline.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2022-02-15; most recent amendment 2025-12-23.
Status change: Not Yet Recruiting → Recruiting 2023-01-05
Trial Details
NCT Number NCT05256745
Lead Sponsor Georgetown University
Conditions Cancer Related Cognitive Decline, Non-metastatic Breast Cancer
Enrollment 48 participants
Start Date 2023-06-06
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-24